Sage Group plc Unsponsored ADR (SGPYY)
OTC PINK OTC PINK Primary 
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
The Sage Group plc (SGGEF) Q1 2025 Earnings Call Transcript
The Sage Group plc (OTCPK:SGGEF) Q1 2025 Earnings Conference Call January 30, 2024 3:30 AM ET Company Participants Jonathan Howell - CFO Conference Call Participants Adam Wood - Morgan Stanley Toby Ogg - JPMorgan Frederic Boulan - Bank of America Charles Brennan - Jefferies Balajee Tirupati - Citi Michael Briest - UBS Jonathan Howell Good morning everyone and welcome to Sage's Q1 Trading Update. I'll briefly run through the key numbers and the performance of the business and after that, we can open for Q&A.
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen.
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen
Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of Sage's shares that it does not already own for $7.22 per share.
Sage Therapeutics Stock Headed for Best Day in 5 Years
Biotech stock Sage Therapeutics Inc (NASDAQ:SAGE) is skyrocketing today, up 33.7% to trade at $7.42 at last glance, after Biogen's (BIIB) proposed takeover, which the company said on Friday it would carefully review.
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
On Friday, Sage Therapeutics Inc. SAGE confirmed that Biogen Inc. BIIB submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.
The Sage Group plc (SGGEF) Q4 2024 Earnings Call Transcript
The Sage Group plc (OTCPK:SGGEF) Q4 2024 Earnings Conference Call November 20, 2024 3:30 AM ET Company Participants Steve Hare - Chief executive officer Jonathan Howell - Chief Financial Officer Conference Call Participants Adam Wood - Morgan Stanley Toby Ogg - J.P. Morgan Rahul Chopra - HSBC Fred Boulan - Bank of America Charles Brennan - Jefferies Michael Briest - UBS Steve Hare Good morning and welcome to Sage's Full-Year Results.
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
On Wednesday, Sage Therapeutics Inc SAGE revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD), an inherited brain disorder that causes nerve cells in the brain to break down and die.
Sage Therapeutics to end Huntington's disease trial after key therapy fails again
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer's disease.
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on Wednesday.
